PIK3CA 抗体
(Phosphoinositide-3-Kinase, Catalytic, alpha Polypeptide (PIK3CA))
Phosphatidylinositol 3-kinase is composed of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit. The protein encoded by this gene represents the catalytic subunit, which uses ATP to phosphorylate PtdIns, PtdIns4P and PtdIns(4,5)P2. This gene has been found to be oncogenic and has been implicated in cervical cancers. [provided by RefSeq, Jul 2008].
recommended
recommended
recommended
PIK3CA 适用: 人, 小鼠, 大鼠, Cow, 兔 WB, ELISA, IF (cc), IF (p), IHC (p), IHC (fro), ICC 宿主: 兔 Polyclonal unconjugated
PIK3CA 抗体 by Grade
Find PIK3CA 抗体 with a specific Grade. The Grade listed below are among those available. Click on a link to go to the corresponding products.
PIK3CA 抗体 by 适用
Find PIK3CA 抗体 for a variety of species such as anti-Human PIK3CA, anti-Mouse PIK3CA, anti-Cow PIK3CA. The species listed below are among those available. Click on a link to go to the corresponding products.
PIK3CA 抗体 by 抗体来源
Find PIK3CA 抗体 with a specific 抗体来源. The 抗体来源 listed below are among those available. Click on a link to go to the corresponding products.
PIK3CA 抗体 by 克隆形成能力
Find available monoclonal or polyclonal PIK3CA 抗体. Click on a link to go to the corresponding products.
PIK3CA 抗体 by 克隆
Find PIK3CA 抗体 with a specific 克隆. The 克隆 listed below are among those available. Click on a link to go to the corresponding products.
Popular PIK3CA 抗体
Product
Reactivity
Application
Validations
Cat. No.
Quantity
Datasheet
Reactivity
Human
Application
WB, IHC, IF
Validations
- (3)
- (6)
Cat. No.
ABIN3020829
Quantity
100 μL
Datasheet
Datasheet
Reactivity
Human
Application
WB, ELISA, FACS, IF/ICC
Validations
- (7)
Cat. No.
ABIN1844691
Quantity
100 μL
Datasheet
Datasheet
Reactivity
Cow, Human, Mouse, Rabbit, Rat
Application
WB, ELISA, IF (cc), IF (p), IHC (p), IHC (fro), ICC
Validations
- (1)
- (3)
Cat. No.
ABIN677198
Quantity
100 μL
Datasheet
Datasheet
Reactivity
Human
Application
WB, IHC (p), FACS
Validations
- (3)
- (3)
Cat. No.
ABIN1882113
Quantity
400 μL
Datasheet
Datasheet
Reactivity
Human
Application
WB, IHC, ELISA
Validations
- (5)
Cat. No.
ABIN3028924
Quantity
0.4 mL
Datasheet
Datasheet
Reactivity
Cow, Human, Mouse
Application
WB, ELISA, IF (cc), IF (p), IHC (p), IHC (fro)
Validations
- (3)
Cat. No.
ABIN711521
Quantity
100 μL
Datasheet
Datasheet
Reactivity
Human
Application
IHC, ELISA
Validations
- (1)
- (2)
Cat. No.
ABIN334459
Quantity
100 μg
Datasheet
Datasheet
Reactivity
Human, Mouse
Application
WB, IHC (p)
Validations
- (3)
Cat. No.
ABIN2854758
Quantity
100 μL
Datasheet
Datasheet
Reactivity
Human
Application
IHC, ELISA, IF
Validations
- (2)
Cat. No.
ABIN7163188
Quantity
100 μg
Datasheet
Datasheet
Reactivity
Human
Application
WB, ELISA, IF
Validations
- (2)
Cat. No.
ABIN7127762
Quantity
100 μL
Datasheet
Datasheet
Reactivity
Human
Application
ELISA, PLA
Validations
- (2)
Cat. No.
ABIN562228
Quantity
100 μg
Datasheet
Datasheet
Reactivity
Human, Mouse, Rat
Application
WB
Validations
- (1)
Cat. No.
ABIN2178474
Quantity
100 μL
Datasheet
Datasheet
Reactivity
Human
Application
IHC, IHC (p)
Validations
- (1)
Cat. No.
ABIN2626810
Quantity
50 μL
Datasheet
Datasheet
Reactivity
Mouse
Application
WB
Validations
- (1)
Cat. No.
ABIN5651062
Quantity
100 μg
Datasheet
Datasheet
Reactivity
Mouse
Application
WB
Validations
- (1)
Cat. No.
ABIN5651075
Quantity
100 μg
Datasheet
Datasheet
Latest Publications for our PIK3CA 抗体
: "Berberine inhibits IL-21/IL-21R mediated inflammatory proliferation of fibroblast-like synoviocytes through the attenuation of PI3K/Akt signaling pathway and ameliorates IL-21 mediated ..." in: Cytokine, Vol. 106, pp. 54-66, (2018) (PubMed).: "miR-25-3p, Positively Regulated by Transcription Factor AP-2α, Regulates the Metabolism of C2C12 Cells by Targeting Akt1." in: International journal of molecular sciences, Vol. 19, Issue 3, (2018) (PubMed).
: "Ginsenoside Rg3 Suppresses Proliferation and Induces Apoptosis in Human Osteosarcoma." in: BioMed research international, Vol. 2018, pp. 4306579, (2018) (PubMed).
: "Knockdown of AKT3 (PKB?) and PI3KCA suppresses cell viability and proliferation and induces the apoptosis of glioblastoma multiforme T98G cells." in: BioMed research international, Vol. 2014, pp. 768181, (2014) (PubMed).
: "Resveratrol attenuates intermittent hypoxia-induced insulin resistance in rats: involvement of Sirtuin 1 and the phosphatidylinositol-4,5-bisphosphate 3-kinase/AKT pathway." in: Molecular medicine reports, Vol. 11, Issue 1, pp. 151-8, (2014) (PubMed).
: "Difference in expression of EGFR, pAkt, and PTEN between oropharyngeal and oral cavity squamous cell carcinoma." in: Oral oncology, Vol. 48, Issue 10, pp. 985-90, (2012) (PubMed).
: "Expression of PIK3CA and FOXP1 in gastric and intestinal non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue type." in: Tumour biology, Vol. 32, Issue 5, pp. 913-20, (2011) (PubMed).
: "Progressive 3q amplification consistently targets SOX2 in preinvasive squamous lung cancer." in: American journal of respiratory and critical care medicine, Vol. 182, Issue 1, pp. 83-91, (2010) (PubMed).
: "PIK3CA alterations in Middle Eastern ovarian cancers." in: Molecular cancer, Vol. 8, pp. 51, (2009) (PubMed).
: "Epigenetic repression of DNA mismatch repair by inflammation and hypoxia in inflammatory bowel disease-associated colorectal cancer." in: Cancer research, Vol. 69, Issue 16, pp. 6423-9, (2009) (PubMed).
Aliases for PIK3CA 抗体
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) 抗体Phosphoinositide-3-kinase, catalytic, alpha polypeptide (GL50803_14855) 抗体
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (pik3ca) 抗体
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (Pik3ca) 抗体
phosphoinositide-3-kinase regulatory subunit 1 (Pik3r1) 抗体
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (Pik3ca) 抗体
6330412C24Rik 抗体
AA414921 抗体
C-P3K 抗体
C530050K14 抗体
caPI3K 抗体
CLOVE 抗体
CWS5 抗体
MCAP 抗体
MCM 抗体
MCMTC 抗体
p50alpha 抗体
p55alpha 抗体
p85alpha 抗体
p110 抗体
p110-alpha 抗体
p110alpha 抗体
pi3-k 抗体
PI3-kinase 抗体
PI3K 抗体
pi3k 抗体
PI3K-alpha 抗体
您还需要查找其他产品吗？
You are here:
